Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus

Executive Summary

Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.

You may also be interested in...



BioNTech On The Evolving COVID-19 Vaccine Strategy

The path for developing a variant-adapted COVID-19 vaccine remains uncertain, but the company expects to have more clarity following an FDA advisory committee meeting in June.

Arcturus Could Find Its COVID-19 Vaccine Limited To Smaller Markets

The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.

Moderna’s COVID Vaccine Had Longer FDA Review Than Pfizer’s; Similar Post-Market Requirements

Moderna fell behind Pfizer after receiving EUA for Spikevax, as it took three months longer to file its BLA and had an extra two months of FDA review for full approval. Novavax files request for FDA emergency use authorization of its vaccine.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel